ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 206 participants.

Also called NCT02319005

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 206 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02319005
Other papers using this trial's data
  • Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR) Cardiovascular drugs and therapy, 2020-06 DOI, PubMed 32062791, PMC7242280 PubMed links an erratum for this paper. Erratum: PMID 32548685 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Belgium, Canada, France, Germany, Italy, Spain, Sweden, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02319005. Randomized; double masking; primary purpose treatment. Start 2014-12 (registry gives no type); primary completion 2017-03-30 (actual). Results posted on 2018-07-18.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)
Condition
Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)
Condition
Amyloidosis, Hereditary
Condition
Amyloid Neuropathies, Familial
Condition
Amyloid Neuropathies
Condition
Amyloidosis, Hereditary, Transthyretin-Related
Condition
Familial Transthyretin Cardiac Amyloidosis
Intervention (Drug)
Revusiran (ALN-TTRSC)
Intervention (Drug)
Sterile Normal Saline (0.9% NaCl)
Lead sponsor
Alnylam Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct02319005
Content hash
83c8abb176d361e216c3cfa906f75f1ba42776fed44bfe6ee30f244f22417f44